ID Proteins May Reduce Aggressiveness of Thyroid Tumors

We examinedID expression and their correlation with diagnostic and prognostic features aiming to find a clinical application in differentiated thyroid carcinoma (DTC) cases. mRNA levels ofID1,ID2,ID3, andID4 genes were quantified and their expression was observed by immunohistochemistry in 194 thyroid samples including 68 goiters, 16 follicular adenomas, 75 classic papillary thyroid carcinomas, 18 follicular variants of papillary thyroid carcinoma, 5 follicular thyroid carcinomas, and 1 anaplastic thyroid cancer, besides 11 normal thyroid tissues. DTC patients were managed according to standard protocols and followed up forM = 28 ± 16 months.ID2,ID3, andID4 mRNA levels were higher in benign (2.0  ± 1.9; 0.6 ± 0.6; and 0.7 ± 1.0 AU, respectively) than those in malignant nodules (0.30 ± 0.62; 0.3 ± 0.3; and 0.2 ± 0.3 AU, respectively,p <  0.0001 for all three genes) and were associated with no extra thyroid invasion or metastasis at diagnosis.ID3 nuclear protein expression was higher in benign than that in malignant cells (5.2  ± 0.9 vs 3.0 ± 1.8 AU;p <  0.0001). On the contrary, the cytoplasmic expression ofID3 was higher in malignant than that in benign lesions (5.7  ± 1.5 vs 4.0 ± 1.4 AU;p <  0.0001). Our data indicate thatID genes are involved in thyroid tumorigenesis and suggest these genes act impeding the evolution of more aggressive phenotypes. The different patterns of their tissue expres...
Source: Endocrine Pathology - Category: Pathology Source Type: research